



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Research Article

Synthesis, Characterization and Antibacterial Activity of New Series of Sulfamethoxazole Derivatives

Komal Singh*, Govind Nagar, Manisha Tandon

RKDF College Of Pharmacy, Bhopal.

ARTICLE INFO

Published: 08 Sept. 2025

Keywords:

Sulfamethoxazole,
Synthesis, Sulfamethoxazole
Derivative, Antibiotic

DOI:

10.5281/zenodo.17075508

ABSTRACT

Sulfamethoxazole (SMX) belongs to the sulfonamide group of antibiotics. It was chosen to represent this group because it is widely used and detected in aquatic environments. The thiazolidine ring has been incorporated into many well-known biologically active compounds, either as an additional component or by replacing another ring, prompting researchers to develop several compounds with this structure. Furthermore, the chemistry of chalcones has produced serious scientific readings throughout the world. Chiefly, interest has been concentrated on the creation and biodynamic actions of chalcones so that a diversity of novel heterocycles with favorable pharmaceutical shape can be designed. Synthetic procedures have been successfully developed for the generation of the target compounds. Six different aromatic parabenaldehydes (H, OH, OCH₃, NO₂, Cl, & N(CH₃)₂) were used, following a multi-step reaction procedure. The purity of the products was checked by using thin-layer chromatography (TLC). The chemical structure of the intermediate and final compounds was identified and verified by checking their melting points, using FT-IR spectroscopy, performing elemental microanalysis (CHNS), and analyzing the final compounds with ¹H NMR. A preliminary study of antimicrobial activity was conducted on three different strains of bacteria, revealing that the final compounds M3(a-f) exhibit significant activity compared to the standard drug sulfamethoxazole, with moderate to favorable activity.

INTRODUCTION

Fungal and bacterial infections represent a major public health problem currently. Despite the huge range of antimicrobial drugs available and their

medicinal-chemical evolution, the indiscriminate use of these drugs has resulted in the emergence of resistant pathogens. The microbial resistance imposes serious limitations on options for treatment and has caused great harm to public

***Corresponding Author:** Komal Singh

Address: RKDF College Of Pharmacy, Bhopal.

Email ✉: pritisingh4205@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



health, since it is the primary cause of death in intensive care units in hospitals worldwide.[1] It is estimated that more than 70% of pathogenic bacteria develop resistance to at least one antibiotic available for clinical use.[2] Thus, the continuing need for novel therapeutic compounds is still urgent as regards the number of new diseases and resistant strains of microorganisms.[3,4] The heterocyclic compounds are very widely distributed in nature and are very essential to living organisms. They play a vital role in the metabolism of all the living cells. Among large number of heterocycles found in nature, nitrogen heterocycles are the most abundant specially those containing oxygen or sulfur[5], due to their wide distribution in nucleic acid illustration and their involvement in almost every physiological process of plants and animals. Heterocyclic compounds possess great applicability in industry as well as in our life in various ways. For example greatest of the sugars and their derivatives, including vitamin C.[6] Therefore, series of sulfa drugs, sulfamethoxazole substituted 5-arylidene -4-thiazolidinone, compounds have been designed and synthesized, these compounds expected to have higher antimicrobial than sulfamethoxazole, due to 4-thiazolidinone scaffold which is very versatile and has featured in a number of clinically used drugs. They have found uses as antibacterial[7], antitubercular[8], antiviral agents, especially as anti-HIV agents[9], antifungal[10], as well as anticancer activity[11], anti-inflammatory and analgesic activity.[12] Sulfamethoxazole was chosen since its effective against both gram-positive and gram negative bacteria and inhibits growth by a competitive binding to dihydropteroate synthetase which stops the conversion of para-aminobenzoate (PABA) to dihydropteroate, a precursor to tetrahydrofolic acid, which is essential for the synthesis of nucleic acids. An additional mechanism of action is that

sulfonamides block cross-membrane transport of glutamic acids which also is an essential component for synthesizing folic acid.[13] Substituted 5-arylidene -4-thiazolidinone moiety shows an essential role as antimicrobial agent, compound [I] & [II] as well as potential anti-inflammatory agent, compound [III]. As shown in figure 1. Therefore, a substituted 5-arylidene -4-thiazolidinone, pharmacophore derivatives derived from amine group of a sulfamethoxazole were designed, synthesized and evaluated as antibacterial agents.

MATERIALS AND METHODS

2.1. Chemicals and Instrumentation

All reagents and anhydrous solvents were of analar type and generally used as received from the commercial suppliers (BDH, England, Merck, Germany, Fluka AG Switzerland, and Sigma-Aldrich, Germany). Sulfamethoxazole was supplied by the wadi al-rafidain factory Iraq. Melting points were determined by capillary method by using FTIR Shimadzu (Japan), ¹HNMR bands (solvent DMSO-d₆) were documented on 300 MHz spectrometer (Bruker DMX-500) spectrophotometer with TMS as internal standard, Electric melting point apparatus and ascending thin layer chromatography (TLC) to check the purity and progress of reactions was run on Kieslgel GF254 (60) aluminum plates, E. Merck (Germany). The identification of compounds was done using IR spectra were recorded on a FTIR- spectrophotometer Shimadzu as KBr disks in University of Al-Mustansiriyah, at college of pharmacy. CHNS microanalysis was done using a Perkin-Elmer model elemental analyzer (Italy) in chemistry department, AL-Byat University, Jordan. ¹HNMR bands were documented on 300 MHz spectrometer in AL-Byat University, Jordan, at chemistry department. The antimicrobial activity of the final compounds



was done in City of Medicine / educational laboratories section. A preliminary antibacterial and antifungal activity have been carried out according to Well Diffusion Method.

2.2. Synthesis

2.2.1 Chemical Synthesis of Schiff base [4-((4-methoxybenzylidene)amino)-N-(5-methylisoxazol-3-yl)benzenesulfonamide] (M1)

The schiff-base was prepared by the usual condensation reaction, in which equimolar (0.01 mol, 1.362 g) of p- methoxybenzaldehyde and the amine (Sulfamethoxazole) (0.01 mol, 2.533 g) were dissolved in minimum amount of ethanol .Glacial acetic acid(2 mL) was added and refluxed for about 6-8 hr the reaction was checked by TLC using Petroleum ether/ ethyl acetate (7:3), then cools at room temperature and the content was poured on crushed ice.[14]. The yellow crystalline product was collected through filtration.(yield 88%) with melting point at 234-236°C. Rf value : 0.54. The FT-IR spectral data for the previous compound shows NH Stretching vibration of secondary sulfonamide at (3400 cm⁻¹), ν C=N Stretching vibration of imine at (1658 cm⁻¹) ,¹H-NMR spectra showed the singlet for CH=N Imine proton at 8.97 (δ ,ppm). **2.2.2 Synthesis of 4-(2-(4-methoxyphenyl)-4-oxothiazolidin-3-yl)-N-(5-methylisoxazol-3-yl)benzenesulfonamide (M2).**

A mixture of Schiff base (2.98g, 0.01 mol), thioglycolic acid (2.5 mL, 0.022 mol) in N, N dimethylformamide (20 mL) with a pinch of anhydrous ZnCl₂, was refluxed for 12h, the progress of the reaction was checked by TLC using toluene: ether (3:1) as an eluent. The reaction mixture was cooled to room temperature and then poured into crussed ice. The solid thus separated was filtered, washed several times with water.[15] Off white powder (yield 95%) with m.p. 94-96°C. Rf value : 0.64. The FT-IR spectral data for the

previous compound shows NH Stretching vibration of secondary sulfonamide at (3377 cm⁻¹), ν C=O Stretching vibration of thiazolidinone at (1705 cm⁻¹) . ¹H-NMR spectra showed the singlet for Aromatic C-NH at 10.97(δ ,ppm), singlet for CH₂ of thiazolidinone at region 6.02(δ ,ppm), doublet for CH of thiazolidinone at regions 6.51(δ ,ppm).

2.2.3 Synthesis of chalcone compounds [M3-M8]

In a 250 ml round bottom flask , put a combination of compound M2 (0.01 mol) and an aromatic aldehyde (0.012 mol , 4.455 g) in absolute ethanol (50-55 ml) was refluxed with piperidine (1-3 drops) for 6-14 hours .the development of the reaction was tested by TLC using methanol/ chloroform/ ether (4: 3: 3) . The composite was filtered and washed with cold, dry toluene and dry ethanol and after that recrystallized form dry ethanol.[16]

(Z)-4-(5-benzylidene-2-(4-methoxyphenyl)-4-oxothiazolidin-3-yl)-N-(5-methylisoxazol-3-yl)benzenesulfonamide [M3]: Pale-yellow yield of 67% and Rf value at 0.71 , the FT-IR spectra shows characteristic absorption bands at 3367 cm⁻¹ is for ν NH stretching of secondary sulfonamide , bands in region 1668 cm⁻¹refer to ν C=O stretching of thiazolidinone. ¹H-NMR spectra showed the singlet at δ (11.1- ppm) integrated for aromatic -NH amide proton ,The spectrum also shows the singlet signal at δ (4.11- ppm) integrated CH of thiazolidinone ; CHNS calculated (C₂₇H₂₃N₃O₅S₂) C,60.77; H,4.34 ;N,7.87 ; S,12.02; found C,60.45 ; H, 4.17 ; N,7.87 ; S,12.05. **(Z)-4-(5-(4-hydroxybenzylidene)-2-(4-methoxyphenyl)-4-oxothiazolidin-3-yl)-N-(5-methylisoxazol-3-yl)benzenesulfonamide [M4]:** Yellowish brown yield of 62% and Rf value at 0.52 , the FT-IR spectra shows characteristic absorption bands at 3452 cm⁻¹ is for Phenolic ν C-OH stretching , 3223



cm⁻¹ is for ν NH stretching of secondary sulfonamide, bands in region 1680 cm⁻¹ refer to ν C=O stretching of thiazolidinone. ¹H-NMR spectra showed that δ (9.91- ppm) integrated for aromatic -NH amide proton overlapped with aromatic C-OH, The spectrum also shows the singlet signal at δ (3.74- ppm) integrated CH of thiazolidinone. CHNS calculated (C₂₇H₂₃ N₃ O₆S₂) C, 59.00; H, 4.22; N, 7.65; S, 11.67; found C, 59.28; H, 4.05; N, 7.77; S, 11.56. (Z)-4-(5-(4-methoxybenzylidene)-2-(4-methoxyphenyl)-4-oxothiazolidin-3-yl)-N-(5-methylisoxazol-3-yl)benzenesulfonamide [M5]: Pale brown yield of 73% and R_f value at 0.64, the FT-IR spectra shows characteristic absorption bands at 3452 cm⁻¹ is for ν NH stretching of secondary sulfonamide, bands in region 1701 cm⁻¹ refer to ν C=O stretching of thiazolidinone and ν C=N stretching of isoxazole ring at 1637 cm⁻¹. ¹H-NMR spectra showed the singlet at δ (9.77- ppm) integrated for aromatic -NH amide proton, The spectrum also shows the singlet signal at δ (5.15- ppm) integrated CH of thiazolidinone, also shows the Multiplet (6H) δ (4.04- ppm) integrated 2(para-OCH₃). CHNS calculated (C₂₈H₂₅ N₃ O₆S₂) C, 59.67; H, 4.47; N, 7.46; S, 11.38; found C, 59.46; H, 4.415; N, 7.51; S, 11.58. (Z)-4-(2-(4-methoxyphenyl)-5-(4-nitrobenzylidene)-4-oxothiazolidin-3-yl)-N-(5-methylisoxazol-3-yl)benzenesulfonamide [M6]: dark Yellow(pale-brown) yield of 74% and R_f value at 0.88, the FT-IR spectra shows characteristic absorption bands at 3452 cm⁻¹ is for ν NH stretching of secondary sulfonamide, bands in region 1732.13 cm⁻¹ refer to ν C=O stretching of thiazolidinone and ν C=N stretching of isoxazole ring at 1635.69 cm⁻¹, bands in region 1525.74 cm⁻¹ refer to NO₂ asymmetric stretching, bands in region 1350.22 cm⁻¹ refer to NO₂ symmetric stretching. ¹H-NMR spectra showed the singlet at δ (10.98- ppm) integrated for aromatic -NH amide proton, The spectrum also shows the singlet signal at δ (5.33- ppm) integrated CH of thiazolidinone.

CHNS calculated (C₂₇H₂₂ N₄ O₇S₂) C, 56.05; H, 3.83; N, 9.68; S, 11.08; found C, 56.06; H, 3.72; N, 9.78; S, 11.05. (Z)-4-(5-(4-chlorobenzylidene)-2-(4-methoxyphenyl)-4-oxothiazolidin-3-yl)-N-(5-methylisoxazol-3-yl)benzenesulfonamide [M7]: Pale-yellow yield of 75% and R_f value at 0.81, the FT-IR spectra shows characteristic absorption bands at 3448 cm⁻¹ is for ν NH stretching of secondary sulfonamide, bands in region 1732 cm⁻¹ refer to ν C=O stretching of thiazolidinone and ν C=N stretching of isoxazole ring at 1637 cm⁻¹, band in region 1089 cm⁻¹ refer to C-Cl stretching. ¹H-NMR spectra showed the singlet at δ (11.0- ppm) integrated for aromatic -NH amide proton, The spectrum also shows the singlet signal at δ (4.11- ppm) integrated CH of thiazolidinone. CHNS calculated (C₂₇H₂₂ N₃ O₅S₂Cl) C, 57.09; H, 3.90; N, 7.40; S, 11.29; found C, 57.12; H, 3.71; N, 7.39; S, 11.3. (Z)-4-(5-(4-(dimethylamino)benzylidene)-2-(4-methoxyphenyl)-4-oxothiazolidin-3-yl)-N-(5-methylisoxazol-3-yl)benzenesulfonamide [M8]: Orange yield of 74% and R_f value at 0.77, the FT-IR spectra shows characteristic absorption bands at 3431 cm⁻¹ is for ν NH stretching of secondary sulfonamide, bands in region 1720 cm⁻¹ refer to ν C=O stretching of thiazolidinone and ν C=N stretching of isoxazole ring at 1647 cm⁻¹, band in region 1396 cm⁻¹ refer to C-N(CH₃)₂ stretching. ¹H-NMR spectra showed the singlet at δ (10.93- ppm) integrated for aromatic -NH amide proton, The spectrum also shows the singlet signal at δ (5.66- ppm) integrated CH of thiazolidinone, also shows the singlet signal at δ (3.03- ppm) integrated N(CH₃)₂. CHNS calculated (C₂₉H₂₈ N₄ O₅S₂) C, 60.40; H, 4.89; N, 9.72; S, 11.12; found C, 60.22; H, 5.06; N, 9.52; S, 11.15.

2.3. Biological Evaluation

2.3.1 Antimicrobial Activity:[17,18]



The antimicrobial activity of the final compounds was done in City of Medicine / educational laboratories section. A preliminary antibacterial has been carried out according to Well Diffusion Method: The synthesized compounds have been studied for their antimicrobial activity in vitro against three tested bacteria (*Escherichia coli* and *Pseudomonas aeruginosa*, as gram negative bacteria and *Staphylococcus aureus*, as gram positive bacteria) were clinical activated and maintained on nutrient agar medium for testing antibacterial activity. Sulfamethoxazole was used as a standard drug for antibacterial activity.

2.3.2 Sensitivity Assay

The antibacterial activities of the each derivatives compound were determined by agar well diffusion assay was carried out by using pure isolates of three type of bacteria was first subcultured in Brain heart infusion broth at temperature 37°C for 18-24 hour. select 3-5 colonies of bacteria isolates by loop and transfer them to tube containing 3 mL normal saline and vortex well. Approximately one hundred microliters of the standardized inoculum bacterial suspension of around (1.5×10^8 CFU/mL) gained from McFarland turbidity standard (number 0.5). of each bacteria was used to inoculated by use glass spreader on the surface of Mueller Hinton Agar (MHA) plates. The additional liquid was air dried under a sterile hood or repeat the spreading process. the plate were allowed to dry and punched wells (five) in diameter 6 mm. into agar. Subsequently, In each agar plate of tested bacteria five wells were made and (100 µl) of dilutions of derivatives compound (500, 250, 125 and 62.5) introduced into wells on MHA plate. DMSO used as the negative controller. The plates were keep warm at 37 °C for 24 hours and the antimicrobial action was estimated by determining the diameter of the inhibition zone (IZ) all over the

place the disc in mm. The valuation of antibacterial action was based on extent of the diameter of inhibition zone formed all over the place the well.

2.3.3 Preparation of serial dilutions of new synthesized compounds

Take 0.01 g from each compounds and put it in test tube, dissolve it in 10 mL DMSO solvent (this is the stock solution 1000 µg/mL) Take 2.5 mL from the stock solution put it in another test tube and add 2.5 mL from DMSO solvent here made (500 µg/mL) (1st dilution) Take 2.5 mL from the first dilution solution put it in another test tube and add 2.5 mL from DMSO solvent here made (250 µg/mL) (2nd dilution) Take 2.5 mL from the 2nd dilution solution put it in another test tube and add 2.5 mL from DMSO solvent here made (125 µg/mL) (3rd dilution) Take 2.5 mL from the 3rd dilution solution put it in another test tube and add 2.5 mL from DMSO solvent here made (62.5 µg/mL) (4th dilution) This process repeated for all the synthesized compounds (M3-8) also for Sulfamethoxazole was used as a standard drug. The assessment of antibacterial activity was based on measurement of the diameter of inhibition zone formed around the well, and show that the zone of inhibition increased with the increasing of concentration of the tested compounds.

RESULT AND DISCUSSION

3.1. Chemistry

For the synthesis of the target sulfamethoxazole derivatives, the reaction series are drawn in scheme 1. The assessment of antibacterial was based on dimension of the diameter of inhibition zone formed round the well, and display that the zone of inhibition increased with the increasing of concentration of the tested compounds. All the tested compounds show activity against gram – ve

Pseudomonas aeruginosa strain unlike the parent compound sulfamethoxazole, with highest activity for chloro and nitro containing derivatives and lowest activity for the hydroxyl derivative. While for G-ve *E. coli* strain the tested compounds show comparable effects to the parent compound with the highest activity for chloro derivative and lowest one for the hydroxyl derivative. Regarding G+ve *Staphylococcus aureus* strain the highest activity for nitro and chloro derivatives and comparable activity with sulfamethoxazole for remaining derivatives.

CONCLUSION

The antibacterial results showed that the effect of tested compounds increases with the concentration. All tested compounds maintained or increased activity against the tested G+ ve and G-ve bacteria. with highest activity for chloro derivative and lowest for hydroxyl derivative, these results encourage for study other antimicrobial activity like antifungal.

ACKNOWLEDGEMENTS

We are grateful to the staff members and Colleagues of the Department of Pharmaceutical Chemistry/college of pharmacy/Al-mustansiriya University for their help and support.

REFERENCES

1. Mohr KI. History of antibiotics research. In: Sass P, editor. *How to Overcome the Antibiotic Crisis: Facts, Challenges, Technologies and Future Perspectives*. Springer; 2016. p. 237-272. https://doi.org/10.1007/82_2016_499 PMID:27738915
2. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. *Curr Opin Microbiol.* 2019; 51:72-80. <https://doi.org/10.1016/j.mib.2019.10.008> PMID:31733401
3. Nii-Trebi NI. Emerging and neglected infectious diseases: insights, advances, and challenges. *Biomed Res Int.* 2017; 2017(1):5245021. <https://doi.org/10.1155/2017/5245021> PMID:28286767 PMCID:PMC5327784
4. Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev.* 2010; 74(3):417-433. <https://doi.org/10.1128/MMBR.00016-10> PMID:20805405 PMCID:PMC2937522
5. Breijyeh Z, Jubeh B, Karaman R. Resistance of gram-negative bacteria to current antibacterial agents and approaches to resolve it. *Molecules.* 2020; 25(6):1340. <https://doi.org/10.3390/molecules25061340> PMID:32187986 PMCID:PMC7144564
6. Levy SB. *The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle*. Springer; 2013.
7. Epand RM, Walker C, Epand RF, Magarvey NA. Molecular mechanisms of membrane targeting antibiotics. *Biochim Biophys Acta Biomembr.* 2016; 1858(5):980-987. <https://doi.org/10.1016/j.bbamem.2015.10.018> PMID:26514603
8. Lade H, Kim JS. Bacterial targets of antibiotics in methicillin-resistant *Staphylococcus aureus*. *Antibiotics.* 2021; 10(4):398. <https://doi.org/10.3390/antibiotics10040398> PMID:33917043 PMCID:PMC8067735
9. Wright GD. Bacterial resistance to antibiotics: enzymatic degradation and modification. *Adv Drug Deliv Rev.* 2005; 57(10):1451-1470. <https://doi.org/10.1016/j.addr.2005.04.002> PMID:15950313
10. Prescott JF. Sulfonamides, diaminopyrimidines, and their combinations. In: Giguère S, Prescott JF, Dowling PM, editors. *Antimicrobial Therapy in Veterinary*



- Medicine. Wiley-Blackwell; 2013. p. 279-294.
<https://doi.org/10.1002/9781118675014.ch17>
11. Henry RJ. The mode of action of sulfonamides. *Bacteriol Rev.* 1943; 7(4):175-262. <https://doi.org/10.1128/br.7.4.175-262.1943> PMid:16350088 PMCID:PMC440870
12. Smilack JD. Trimethoprim-sulfamethoxazole. In: *Mayo Clin Proc.* Elsevier; 1999. <https://doi.org/10.4065/74.7.730> PMid:10405706
13. La Farre M, Pérez S, Kantiani L, Barceló D. Fate and toxicity of emerging pollutants, their metabolites and transformation products in the aquatic environment. *TrAC Trends Anal Chem.* 2008; 27(11):991-1007. <https://doi.org/10.1016/j.trac.2008.09.010>
14. Mohammed Abd Al-Khaliq Z. Synthesis, characterization and antibacterial activity of new series of sulfamethoxazole derivatives. Ministry of Higher Education; 2015.
15. Ashraf MA, Maah MJ, Yusoff I, Wajid A. Synthesis, characterization and biological activity of Schiff bases. *IPCBEE.* 2011; 10(1):185.
16. Lemire JA, Harrison JJ, Turner RJ. Antimicrobial activity of metals: mechanisms, molecular targets and applications. *Nat Rev Microbiol.* 2013; 11(6):371-384. <https://doi.org/10.1038/nrmicro3028> PMid:23669886
17. Krátký M, Vinšová J, Stolaříková J, et al. Sulfadiazine salicylaldehyde-based Schiff bases: Synthesis, antimicrobial activity and cytotoxicity. *Molecules.* 2017; 22(9):1573. <https://doi.org/10.3390/molecules22091573> PMid:28925956 PMCID:PMC6151383
18. Dua R, Shrivastava S, Sonwane SK, Srivastava S. Pharmacological significance of synthetic heterocycles scaffold: a review. *Adv Biol Res.* 2011; 5(3):120-144.
19. Jain AK, Vaidya A, Ravichandran V, Kashaw SK, Agrawal RK. Recent developments and biological activities of thiazolidinone derivatives: A review. *Bioorg Med Chem.* 2012; 20(11):3378-3395. <https://doi.org/10.1016/j.bmc.2012.03.069> PMid:22546204
20. Zayed MF. Medicinal chemistry of quinazolines as analgesic and anti-inflammatory agents. *ChemEngineering.* 2022; 6(6):94. <https://doi.org/10.3390/chemengineering6060094>
21. Bukhari NA, Jasamai M, Jantan I. Synthesis and biological evaluation of chalcone derivatives (mini review). *Mini Rev Med Chem.* 2012; 12(13):1394-1403. <https://doi.org/10.2174/13895575112091394> PMid:22876958
22. Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones. *Eur J Med Chem.* 2007; 42(2):125-137. <https://doi.org/10.1016/j.ejmech.2006.09.019> PMid:17112640
23. Rajamanickam G, Suresh V, Jayakumar R, et al. In vitro anthelmintic and antimicrobial activity of novel series of quinoxaline-2,3-dione-6-sulphonyl benzimidazoles. *J Chem Pharm Sci.* 2015; 8:656-660.
24. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. *J Pharm Pharm Sci.* 2008; 11(2):81s-110s. <https://doi.org/10.18433/J3T886> PMid:19203472.

HOW TO CITE: Komal Singh*, Govind Nagar, Manisha Tandon, Synthesis, Characterization and Antibacterial Activity of New Series of Sulfamethoxazole Derivatives, *Int. J. of Pharm. Sci.*, 2025, Vol 3, Issue 9, 863-869 <https://doi.org/10.5281/zenodo.17075508>

